Italian Trade Agency at Arab Health supports 160 companies

By HEOR Staff Writer

February 1, 2023

Introduction:

The Italian Trade Agency (ITA) is a government entity promoting Italian products and services. It has thrown its weight behind 160 Italian companies participating in Arab Health 2023.

Arab Health 2023: A Global Healthcare Stage

Arab Health, an annual event that congregates healthcare professionals and companies globally. It is a platform to exhibit the latest products, services, and technological advancements in the healthcare industry. This year’s event, held in Dubai from 30th January to 2nd February, presents a spectrum of healthcare offerings, including innovations like artificial intelligence.

Italian Trade Agency at Arab Health

Located across four different halls, the Italian Pavilion provides a snapshot of Italy’s manufacturing capabilities in the healthcare sector. The pharmaceutical sector, boasting 285 companies employing 67,000 people, stands out for having the most innovative companies. The Italian pharmaceutical industry demonstrates particular prowess in biotech drugs and vaccines. Therefore, establishing Italy as a global hub for research and development (R&D) and production.

Italy’s Vision for the UAE and Sustainability Goals

Lorenzo Fanara, Italy’s Ambassador to the United Arab Emirates (UAE), and Amedeo Scarpa, Italian Trade Commissioner to the UAE, expressed Italy’s vision to strengthen business ties with the UAE, foster long-term investments, and develop industrial partnerships. Under the banner ‘Sustainability is Sustainab-ITALY’, Arab Health 2023 will focus on circular economy and sustainability, reflecting Italy’s pharmaceutical industry’s achievement in reducing energy consumption by 44% over a decade.

Conclusion:

Italian Trade Agency at Arab Health’s support for Italian healthcare companies reflects its commitment to promoting Italy’s robust healthcare sector and its vision for sustainable growth.

Reference url

Recent Posts

NICE Approves Durvalumab for Gastric Cancer Treatment

By HEOR Staff Writer

May 15, 2026

NICE has issued final draft guidance recommending durvalumab, within its marketing authorisation, for use with 5-fluorouracil, leucovorin, oxaliplatin and docetaxel (FLOT) chemotherapy as neoadjuvant and adjuvant treatment, followed by durvalumab monotherapy as adjuvant treatment, in adults with ...
Bladder Cancer Treatment Impact: Barriers to Quality of Life in Patients

By HEOR Staff Writer

A global survey highlights the profound bladder cancer treatment impact on patients with non-muscle-invasive bladder cancer, with more than 90 percent of those undergoing radical cystectomy or BCG therapy reporting negative physical, emotional, and mental health effects. Life-Altering Effect...
Global Growth and Challenges in Pharmacy Vaccination Training

By João L. Carapinha

May 13, 2026

Pharmacy Vaccination Training has expanded rapidly worldwide, with the number of countries offering pharmacist vaccination programs rising from 12 in 2016 to 64 by 2024. This 433 percent growth means training is now available in every nation where pharmacists may administer vaccines, including pr...